Avidity Biosciences, Inc.

Join us this November in celebrating #NationalFamilyCaregiversMonth. As the backbone of the #raredisease community, caregivers work tirelessly to advocate for those they care about as well as advancements in research and care. We want to recognize their time, commitment, and continued contributions. At Avidity, we are committed to listening, learning, and partnering with patients and caregivers as we remain steadfast in our commitment to advance meaningful therapies for the muscular dystrophy community. Read these powerful stories of strength and dedication: https://lnkd.in/eaHk-mpS #NFCMonth #NFCM #FamilyCaregivers #Caregiving

We're excited to share that we have initiated a biomarker cohort in our Phase 1/2 FORTITUDE? clinical trial for people living with facioscapulohumeral muscular dystrophy (#FSHD). The initiation of the biomarker cohort marks a key step in our strategy to pursue a potential accelerated approval path for the first potential treatment to directly target the root cause of FSHD. Currently, there are no approved therapies for the treatment of FSHD, a rare, hereditary disorder marked by life-long, relentless loss of muscle function, significant pain, fatigue, and progressive disability. The community's response and interest in the FORTITUDE study has been tremendous. We are grateful for their partnership and understand the urgency to bring a new treatment to people living with FSHD as quickly as possible. For more information, see our press release: https://lnkd.in/eTmGDgkF

At Avidity, we are driven by our mission to profoundly improve people’s lives by revolutionizing a new class of targeted RNA therapeutics. We are proud to have a team of dynamic and dedicated individuals who are committed to providing new and innovative treatment options for patients and their families. If you’re eager to make a real difference and thrive in a culture that values both professional excellence and personal well-being, Avidity is the place for you. Join us and be part of a team where your contributions fuel innovation and impact lives. Explore our available opportunities: https://lnkd.in/dWCgkwVY #BeAVID

Last week our Chief Program Officer, Kathleen Gallagher, participated in the first FDA Rare Disease Innovation Hub meeting held in collaboration with the Reagan-Udall Foundation for the FDA. The meeting brought together patient advocates, academic researchers, industry members and other key stakeholders to discuss how to best engage with members of the #raredisease community and support rare disease related policies and initiatives. Over 30 million people in the U.S. are affected by rare diseases and many lack effective treatments. The work of the Rare Disease Innovation Hub is crucial in driving progress for these patients. At Avidity, we value the importance of a shared vision as we advance our clinical development programs for #DM1, #FSHD, and #DMD44, working toward bringing much-needed therapies to those living with these devastating rare diseases. Learn more about the Rare Disease Innovation Hub at https://lnkd.in/epxcdyZk and learn more about our ongoing commitment to the #raredisease community at https://lnkd.in/dH-56XKM

We are proud to support the 18th International Congress on Neuromuscular Diseases (ICNMD), organized by the Specialty Group on Neuromuscular Diseases (NMD) of the World Federation Of Neurology (WFN) in Perth, Australia.? We look forward to engaging with the global neuromuscular community, gaining the latest insights into neuromuscular disorders, and fostering valuable networking opportunities and international collaborations. Our team will be on-site to connect with industry leaders and innovators who share our commitment to making a meaningful impact in the lives of individuals with muscular diseases. Learn more about the conference: https://icnmd.org/ #ICNMD24

We are proud to share that Avidity is now a member of EUCOPE - European Confederation of Pharmaceutical Entrepreneurs. As we continue to build a fully integrated global organization, we look forward to working with EUCOPE’s network of industry leaders, patient advocates, and policy experts as we fulfill on our vision to profoundly improve people’s lives by revolutionizing a new class of targeted RNA therapeutics.

This week, Dr. Mike Flanagan, our Chief Scientific and Technical Officer and postdoctoral alum of Stanford University School of Medicine was invited to present a lecture as part of a unique program called SPARK at Stanford on how Avidity is utilizing its proprietary Antibody-Oligonucleotide Conjugates (AOC) platform to profoundly improve people’s lives by revolutionizing a new class of targeted RNA therapeutics. As the first company to demonstrate the successful targeted delivery of RNA to muscle, we have shared unprecedented and consistent data across all three of our clinical development programs for three different types of rare muscle diseases: myotonic dystrophy type 1 (#DM1), facioscapulohumeral muscular dystrophy (#FSHD) and Duchenne muscular dystrophy amenable to exon 44 skipping (#DMD44). We are excited to continue to advance our rare skeletal muscle and rare precision cardiology programs. SPARK at Stanford bridges the gap between discovery and drug treatment through a partnership between university and industry experts. SPARK aims to accelerate the translation of academic discoveries into practical medical applications by offering mentorship, funding, and industry expertise to faculty, postdoctoral researchers, and students. Learn more about our expanding and advancing pipeline: https://lnkd.in/dH-56XKM

October 10 is #WorldMentalHealthDay. This year's theme is "Mental Health at Work", which aims to highlight the vital connection between mental heath and work. At Avidity, we are committed to creating a positive and supportive work culture where every employee feels heard, understood and empowered to succeed. We prioritize the mental and emotional well-being of our team members by providing a safe space, tools and resources so they can navigate challenges and thrive in their personal and professional lives. Learn more about the importance of mental health care by visiting the National Alliance on Mental Illness (NAMI)'s website: https://www.nami.org/

We are thrilled to share that Sarah Boyce, our President and CEO, has been recognized as a 2024 PharmaVoice 100 honoree. This award highlights exceptional leaders in the life sciences who are making a difference through innovation, mentorship, and a genuine commitment to advancing patient care. Sarah’s visionary leadership has been a driving force behind Avidity's pioneering work in antibody-oligonucleotide conjugates (AOCs). Her dedication to developing groundbreaking therapies for rare muscle diseases and beyond truly embodies her passion for improving the lives of patients in need. We are so proud to have her leading our team and inspiring us all to strive for excellence. Congratulations, Sarah, on this well-deserved honor. See here: https://lnkd.in/ekpeFvWP #PharmaVoice100

This week during the 29th Annual Congress of the World Muscle Society, Marcie Fowler, our Executive Director of Clinical Development, will deliver a poster presentation exploring the design of our global Phase 3 HARBOR? trial for myotonic dystrophy type 1 (#DM1).? As we leverage our proprietary AOC platform to advance our clinical development programs for rare muscle diseases, we are excited to support this event and look forward to engaging with colleagues, researchers, and industry leaders from around the world to share the latest science in the field of muscular diseases. Learn more about #WMS2024: https://www.wms2024.com/